Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

6.3K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
6.3K
Cells of the Innate Immune Response01:28

Cells of the Innate Immune Response

8.4K
The innate immune response is an immediate and non-specific response against pathogens, acting swiftly to prevent the spread of infections. The primary cells involved in this response are phagocytes and natural killer (NK) cells.
Phagocytes
Phagocytes police the peripheral tissues by removing cellular debris and responding to the invasion of foreign substances or pathogens. Many phagocytes attack and remove microorganisms even before lymphocytes detect them. The human body has two general...
8.4K
Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

HLA-G expression in non-small cell lung cancer: prognostic significance and interplay with PD-L1 and CD8<sup>+</sup> tumor-infiltrating lymphocytes.

Frontiers in immunology·2026
Same author

The evolution of prostate cancer grading: from Gleason score to risk taxonomy and the artificial intelligence revolution.

Virchows Archiv : an international journal of pathology·2026
Same author

A tissue and cell-level annotated H&E and PD-L1 histopathology image dataset in non-small cell lung cancer.

IEEE journal of biomedical and health informatics·2026
Same author

HLA-E-restricted SARS-CoV-2 epitopes drive CD8<sup>+</sup> T cell memory in convalescent and vaccinated individuals: implications for the design of next-generation vaccines and immunotherapeutics.

Journal of translational medicine·2026
Same author

IL-37/IL-1R8 axis: a novel major mechanism of control at the interface between tumor and immune cells.

Oncoimmunology·2025
Same author

Editorial: Cytokines, and biomarkers involved in the immunomodulation of pediatric cancers.

Frontiers in immunology·2025

Related Experiment Video

Updated: Dec 29, 2025

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

1.6K

Exploiting Human NK Cells in Tumor Therapy.

Paola Vacca1, Gabriella Pietra2,3, Nicola Tumino1

  • 1Immunology Research Area, IRCCS Bambino Gesù Pediatric Hospital, Rome, Italy.

Frontiers in Immunology
|February 4, 2020
PubMed
Summary

Natural killer (NK) cells are crucial for innate immunity against cancer. This review explores various NK cell-based immunotherapies, including cytokine therapy, CAR-NK cells, and checkpoint inhibitors, highlighting their potential to enhance anti-tumor responses.

Keywords:
NK cellsanti-tumor therapyimmunotherapyinhibitory checkpointsinnate immunity

More Related Videos

Expansion, Purification, and Functional Assessment of Human Peripheral Blood NK Cells
10:44

Expansion, Purification, and Functional Assessment of Human Peripheral Blood NK Cells

Published on: February 2, 2011

49.3K
Natural Killer NK and CAR-NK Cell Expansion Method using Membrane Bound-IL-21-Modified B Cell Line
11:02

Natural Killer NK and CAR-NK Cell Expansion Method using Membrane Bound-IL-21-Modified B Cell Line

Published on: February 8, 2022

6.2K

Related Experiment Videos

Last Updated: Dec 29, 2025

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

1.6K
Expansion, Purification, and Functional Assessment of Human Peripheral Blood NK Cells
10:44

Expansion, Purification, and Functional Assessment of Human Peripheral Blood NK Cells

Published on: February 2, 2011

49.3K
Natural Killer NK and CAR-NK Cell Expansion Method using Membrane Bound-IL-21-Modified B Cell Line
11:02

Natural Killer NK and CAR-NK Cell Expansion Method using Membrane Bound-IL-21-Modified B Cell Line

Published on: February 8, 2022

6.2K

Area of Science:

  • Immunology
  • Cancer Biology
  • Immunotherapy

Background:

  • Natural killer (NK) cells are vital components of the innate immune system, crucial for identifying and eliminating tumor cells and preventing metastasis.
  • NK cell activity is tightly regulated by a balance of activating and inhibitory receptors, including those specific for HLA class I molecules, which are often downregulated by tumors.
  • Dysfunctional NK cells are frequently observed in cancer patients, necessitating therapeutic strategies to restore or enhance their anti-tumor functions.

Purpose of the Study:

  • To provide a comprehensive overview of current and emerging NK cell-based immunotherapies for cancer treatment.
  • To discuss the mechanisms of action, advantages, and limitations of various NK cell-directed therapeutic approaches.
  • To highlight the potential of NK cells, particularly engineered CAR-NK cells and their role in combination therapies, for overcoming tumor immune evasion.

Main Methods:

  • Review of existing literature on NK cell biology and cancer immunotherapy.
  • Analysis of different therapeutic strategies involving NK cells: cytokine therapy (IL-2, IL-15), adoptive cell transfer (cytokine-induced NK cells, CAR-NK cells), and antibody-based therapies (checkpoint inhibitors).
  • Discussion of NK cell roles in specific contexts, such as haploidentical hematopoietic stem cell transplantation and response to checkpoint blockade.

Main Results:

  • Cytokine therapy (IL-2, IL-15) can activate and expand NK cells but is limited by toxicity and efficacy in some patients.
  • Adoptive transfer of cytokine-induced NK cells shows promise but can have variable efficacy depending on tumor site.
  • Chimeric antigen receptor (CAR)-NK cells offer an "off-the-shelf" allogeneic therapy option, avoiding graft-versus-host disease (GvHD).
  • NK cells, alongside γδT cells, contribute to reduced leukemia relapse and infections post-haploidentical HSC transplantation.
  • Monoclonal antibodies targeting checkpoint inhibitors (e.g., PD-1, CTLA-4) can enhance NK cell effector functions, especially against tumors with low HLA class I expression.

Conclusions:

  • NK cells represent a versatile platform for cancer immunotherapy with diverse therapeutic applications.
  • CAR-NK cells hold significant potential as an accessible and effective "off-the-shelf" cancer therapy.
  • Targeting immune checkpoints can unleash NK cell-mediated anti-tumor immunity, offering new avenues for treatment, particularly for tumors resistant to T cell-mediated killing.